CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Paclitaxel +2 moredrug
Likely dose
Paclitaxel 20mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02446574
NCT02446574Phase 2Completed
CompareCT.gov

Phase I /II Study of Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma

Chinese Academy of Medical Sciences·interventional·Posted May 18, 2015·Updated Oct 24, 2017

In Brief

A Phase 2 clinical trial evaluating Paclitaxel, Cisplatin, and 1 other intervention for Esophageal Neoplasms. Completed, enrolled 33 participants across 1 site.

Detailed Summary

This is a unicentered phase I/II study to explore the dose of paclitaxel and cisplatin with radiation therapy, and to document the adverse events for further clinical trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Neoplasms
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 18, 2015
Enrollment StartJul 1, 2007
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9.4 yearsPosted 11.1 years ago

Interventions

Paclitaxeldrug

starting dose 20mg/m2 qw

Cisplatindrug

dose 25mg/m2 qw

Radiationradiation

60Gy/2Gy/30f